The more assumptions you have to make, the more unlikely an explanation is.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The company (officers) gave away many shares, not warrants or at a discount, just free. Why don’t the officers get together and buy them back?
Never mind I read your posting history. Sorry you are in such a position.
How did you acquirer the shares?
The asset management firm beat estimates by 19 cents a share, with quarterly profit of $7.15 per share. Revenue came in essentially in line with analyst forecasts. Profit dropped from a year ago, however,
~~~~~~>>>>as investors shifted money to fixed-income funds and other less profitable accounts.
Pr states at end some of their customers related to more conservative investments. Nothing about losing customers or such.
Blackrock—- Stocks making the biggest moves premarket: JP Morgan, Goldman Sachs, BlackRock & more https://www.cnbc.com/2019/10/15/stocks-making-the-biggest-moves-premarket-jp-morgan-goldman-sachs-blackrock-more.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
*Omeros: Inhibition of MASP-2, Key Enzyme of Complement System's Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
9/25/19, 5:47 AM
(MORE TO FOLLOW) Dow Jones Newswires
OMER
That $26.8M is all Omidria at 50% at least $500M
Basics from Q pr below. Good idea to listen to CC. Explains advantages of J-code for Omidria. 10% of market to date. BLA for narsoplimab and what’s next. CEOs thoughts plans on/for MASP-2 and 3.
OMIDRIA® revenues for 2Q 2019 were a record high at $26.8 million. This compares to $21.8 million in 1Q 2019. The increase of $5.0 million, or 23 percent, over the prior quarter reflects both an expanded number of purchasing accounts and deeper penetration across Ambulatory Surgery Centers (ASCs), hospitals and the Veterans Administration and other government systems.
Net loss in 2Q 2019 was $14.5 million, or $0.29 per share, which included non-cash expenses of $6.3 million, or $0.13 per share. This compares to a net loss of $24.3 million, or $0.50 per share, in 1Q 2019.
At June 30, 2019, Omeros had cash, cash equivalents and short-term investments available for operations of $31.8 million and an accounts receivable balance of $28.5 million.
In August 2019, the company entered into a $50-million revolving line of credit facility with Silicon Valley Bank. Borrowing availability is based on eligible accounts receivable, subject to applicable reserves.
OMER good Q making strides.
Great Q tic toc
Whatever happened to the idea of growth in GDP=growth in gov tax "revenue"= lowering debt...oh wait need leaders more interested in the good than the political. Sigh...
Pissst it’s May.
At any rate, if they keep doing what they are doing and start moving through the ranks on OTC the pps will respond.
Why rs at all? Closing price of $2, 300 shareholders, 1M OS, 50MM listed value, 15MM public value, 4MM shrholders equity = Market Value of Listed Securities Standard*
Listing Requirements for All Companies
Each company must have a minimum of 1,250,000 publicly traded shares upon listing, excluding those held by officers, directors or any beneficial owners of more than 10% of the company.
In addition, the regular bid price at time of listing must be $4.00, and there must be at least three market makers for the stock.
However, a company may qualify under a closing price alternative of $3.00 or $2.00 if the company meets varying requirements.
Each listing firm is also required to follow Nasdaq corporate governance rules 4350, 4351 and 4360.
Companies must also have at least 450 round lot (100 shares) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months.
By using HLNE PIOE is positioning as a growth stock.
Thanks for sharing your work Chemist.
Nice!
.30? Who knows? Bears were right on this 1
Picked some up.
Would be fun to know the story behind the buy(s).
Impressive
Sounds reasonable chemist.
Yeah me either, opinion just based on "birds of a feather flock together".
I figure we'll know if they have a shot at uplist if interest increases (volume then price).
I think they'll go for NYSE.
Truth
Canada and US reach deal to replace NAFTA https://www.cnbc.com/2018/10/01/us-canada-nafta-trade-talks.html
DOVA 2 presentations in NY on 10/2:
Oct 2, 2018 at 11:00 AM EDT
http://investors.dova.com/events/event-details/ladenburg-thalmanns-2018-healthcare-conference
Oct 2, 2018 at 5:10 PM EDT
http://investors.dova.com/events/event-details/cantor-fitzgeralds-annual-global-healthcare-conference
DOVA- Salix Ink Exclusive Co-Promotion Deal for DOPTELET (Avatrombopag) in U.S.
DURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that they have entered into an exclusive agreement to co-promote Dova’s DOPTELET (avatrombopag) in the United States (U.S.). The U.S. Food and Drug Administration ("FDA") approved DOPTELET on May 21, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. DOPTELET represents the first thrombopoietin (TPO) receptor agonist approved in the United States for this indication.
Nice swing.
PLUG-one step closer to fleet of delivery trucks:
Plug Power Begins Production of Proprietary Membrane Electrode Assemblies (MEAs), a Key Component of its New ProGen Metal Plate Stack
7:00 am ET September 18, 2018 (Globe Newswire) Print
Leveraging its acquisition of American Fuel Cell, the new ProGen metal plate stack provides twice as much power density and a longer lifecycle for on-road applications
Plug Power Inc. (NASDAQ: PLUG), a leading provider of energy solutions that change the way the world moves, today announced the production of its membrane electrode assemblies (MEAs). Leveraging the expertise gained through its acquisition of American Fuel Cell (AFC) technology in June 2018, Plug Power's proprietary MEA is a key component of the newly designed ProGen metal plate stack. The new stack provides Plug Power with a competitive edge, doubling the power density of its graphite plate stack and extending the life cycle for on-road applications. With this new stack, Plug Power continues its commitment to fuel cell innovation and its goal of accelerating the adoption of zero emission hydrogen fuel cell electric vehicles (HFCVs) through powerful technologies.
Hydrogen fuel cells are the cleanest alternative energy solution available today, with heat and water as the only byproducts. For businesses dependent on the usability and range of delivery vehicles, HFCVs provide markedly improved uptime, offering a sustainable alternative to the lengthy charge times and range anxiety associated with battery-powered electric vehicles (BEVs). With the new ProGen metal plate stack, Plug Power is introducing a robust alternative energy solution that lasts longer and more than doubles standard BEV range, keeping high utilization fleet vehicles on the road longer.
"It's no secret that fuel cell adoption is on the rise. Earlier this year KPMG stated that hydrogen fuel cell electric vehicles have replaced battery-powered electric vehicles as the number one trend until 2025," said Andy Marsh, CEO, Plug Power. "With this increase in popularity, it's critical that we're prepared to address the growing needs of today's customers as well as those on the horizon. Thanks to the recent expansion of our facilities in Rochester and Clifton Park, NY, Plug Power has the infrastructure required to ramp up production of our new ProGen metal plate stack, ensuring we're meeting the demands of this rapidly expanding industry."
A core component of the ProGen metal plate stack, Plug Power developed an ink, catalyst, and material formula for its MEA technology that improves efficiency and enhances durability. Plug Power began manufacturing MEAs in the third quarter of 2018 from Rochester, NY leveraging existing expertise and infrastructure in fuel cell technology as well as thin film coating and roll-to-roll manufacturing.
"Technology innovation is paramount to the success of hydrogen fuel cell adoption, and Plug Power has an established reputation as the industry's leader," said Keith Schmid, COO, Plug Power. "By quickly onboarding the AFC team, we've been able to merge their specialized skill sets in MEAs and on-road applications with Plug Power's unmatched experience in hydrogen fuel cell system design. This collaborative design effort allows our ProGen technology to operate more efficiently, reduce operating costs, and meet sustainability goals."
The ProGen metal plate stack will be integrated into Plug Power's ProGen hydrogen engines, simplifying the advancement of new on-road market development opportunities like delivery vans, buses, and trucks. The newly designed MEAs and metal stacks will improve product performance, cost, and quality.
About Plug Power Inc.
The architect of modern hydrogen and fuel cell technology, Plug Power is the innovator that has taken hydrogen and fuel cell technology from concept to commercialization. Plug Power has revolutionized the material handling industry with its full-service GenKey solution, which is designed to increase productivity, lower operating costs and reduce carbon footprints in a reliable, cost-effective way. The Company's GenKey solution couples together all the necessary elements to power, fuel and serve a customer. With proven hydrogen and fuel cell products, Plug Power replaces lead acid batteries to power electric industrial vehicles, such as the lift trucks customers use in their distribution centers.
Extending its reach into the on-road electric vehicle market, Plug Power's ProGen platform of modular fuel cell engines empowers OEMs and system integrators to rapidly adopt hydrogen fuel cell technology. ProGen engines are proven today, with thousands in service, supporting some of the most rugged operations in the world. Plug Power is the partner that customers trust to take their businesses into the future. Learn more at www.plugpower.com.
DOVA- To host investor and analyst day 9/20:
September 11, 2018
PDF Version
DURHAM, N.C., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announced that the Company will host a live webcast of its Investor & Analyst Day on Thursday, September 20, 2018 beginning at 7:30 a.m. ET in New York City.
Key opinion leaders will discuss their own experiences with DOPTELET® (avatrombopag). In addition, another key opinion leader will discuss the potential opportunities for DOPTELET in additional indications if approved by the U.S. Food and Drug Administration, including immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia (CIT).
In-person attendance requires advance registration. If you would like to attend in-person, please send a RSVP to john.woolford@westwicke.com or call (443) 213-0506.
The live audio webcast of the event will be available through the “Investor Relations” page of the Dova website, www.dova.com. To access the webcast, please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova’s website for 90 days following the event.
Last 8k: “Over the past quarter, we presented scientific data from a series of studies that continue to provide us with confidence in the potency and activity profile of our lead lysin product candidate, CF-301 (exebacase) and the potential of our broader lysin platform,”
Technical lows usually prove to be good buying territory.
Whatever one's thoughts on company, in the Quarterly cycle, the technical low's have proven to be buys.
No idea on details, just talking trend.
A friend works for Hawthorn. He also had a caregiver license allowing him to grow some weed. The price has dropped considerably.
Also the search for a master grower is ongoing in the real world. People need financing or cash to get through the lean years.